Boston Scientific (BSX) vs DexCom (DXCM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
DexCom (DXCM) has outperformed Boston Scientific (BSX) over the past year, gaining 27.4% versus a loss of 56.3%. Over five years, BSX leads with a -3.4% price change compared with -38.2% for DXCM. Boston Scientific is the larger company by market cap ($60.26 billion vs $31.81 billion), about 1.9 times the size.
On valuation, Boston Scientific trades at a lower forward P/E (12.3x vs 27.0x for DexCom). DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 14.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSX | DXCM |
|---|---|---|
| Share price | $41.58 | $84.30 |
| Market cap | $60.26B | $31.81B |
| 1-day change | -1.45% | +1.09% |
| YTD return | -56.01% | +26.80% |
| 1-year return | -56.26% | +27.45% |
| 5-year return | -3.35% | -38.17% |
| P/E ratio (TTM) | 16.83 | 33.45 |
| Forward P/E | 12.29 | 26.96 |
| EPS (TTM) | $2.47 | $2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $20.07B | $4.66B |
| Revenue growth (YoY) | +19.87% | +15.60% |
| Net income (latest FY) | $2.89B | $836.30M |
| Gross margin | 69.01% | 60.10% |
| Operating margin | 18.00% | 19.56% |
| Net margin | 14.41% | 17.94% |
| 52-week high | $105.65 | $92.59 |
| 52-week low | $41.50 | $54.11 |
| Distance from 52-week high | -60.64% | -8.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +44.06% | +14.15% |
| Average volume | 19.67M | 4.48M |
| Shares outstanding | 1.45B | 377.36M |
| Employees | 59,000 | 11,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXCM has outperformed BSX by 83.7 percentage points over the past year.
- DexCom trades at a higher earnings multiple (33.5x vs 16.8x trailing P/E).
About Boston Scientific
BSX stock →Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Healthcare · Medical Devices · 59,000 employees
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Healthcare · Medical Devices · 11,000 employees
BSX vs DXCM FAQ
Which is bigger, Boston Scientific or DexCom?
Boston Scientific (BSX) is larger, with a market capitalization of $60.26B compared with $31.81B for DexCom (DXCM).
Which stock has performed better over the past year, BSX or DXCM?
DXCM returned +27.45% over the past 12 months, compared with -56.26% for BSX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BSX or DXCM?
BSX has the lower trailing P/E at 16.8, versus 33.5 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Boston Scientific and DexCom in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.